Week In Review: 2 Hong Kong IPOs – BeiGene And Ascletis – Raise A Combined $1.3 Billion

China Renaissance’s healthcare fund co-led the round. CDM claims it prices its HIV reagents at about one-third the price of comparable HIV reagents from multinational biopharmas. Curon Biophama, a Sha…
( read original story …)


Related Post